Nifedipine, a slow-channel calcium blocker, is thought to provide useful myocardial
protection during prolonged total ischemia and reperfusion. An isolated, isovolumic, feline …

This report summarizes five years of laboratory investigations and the initial six-month
clinical experience with a calcium antagonist, nifedipine, added to a cold hyperkalcmic …

The effectiveness of the calcium antagonist nifedipine in preserving postischemic
myocardial function and structural integrity was experimentally demonstrated in isolated …

The ability of nifedipine to enhance myocardial protection was assessed using an isolated
rat heart model of cardiopulmonary bypass and ischaemic cardiac arrest. With normothermic …

To determine whether nifedipine, a calcium antagonist, protects ischemic myocardium,
conscious dogs were subjected to coronary occlusion and given nifedipine by intravenous …

This report summarizes studies that provided a basis for a randomized clinical trial of
nifedipine in cold hyperkalemic cardioplegic solution. Data from normothermic, isolated …

This study was designed to compare the effects of the calcium slow channel blocking agents
verapamil (0, 15 mg/kg), diltiazem (0. 15 mg/kg), and nifedipine (50 pg/kg) on the …

Preservation of regional myocardial function, high-energy phosphate stores and
ultrastructure were assessed in 28 canine hearts subjected to 2 hours of global ischemia at …

Experimental studies using animal models designed to mimic the effect of ischemia and
postischemic reperfusion have provided data indicating that the calcium antagonists might …

Previous animal studies and a preliminary clinical trial of the addition of nifedipine to
cardioplegic solution demonstrated salutary effects in terms of postischemic performance …